Redx Pharma PLC
LSE:REDX
Intrinsic Value
Redx Pharma Plc engages in the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. [ Read More ]
The intrinsic value of one REDX stock under the Base Case scenario is 8.98 GBX. Compared to the current market price of 8.06 GBX, Redx Pharma PLC is Undervalued by 10%.
Valuation Backtest
Redx Pharma PLC
Run backtest to discover the historical profit from buying and selling REDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Redx Pharma PLC
Current Assets | 23.3m |
Cash & Short-Term Investments | 18.1m |
Receivables | 5.2m |
Non-Current Assets | 2.3m |
PP&E | 1.9m |
Intangibles | 394k |
Current Liabilities | 21m |
Accounts Payable | 3.8m |
Short-Term Debt | 15.7m |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 1.3m |
Long-Term Debt | 1.3m |
Earnings Waterfall
Redx Pharma PLC
Revenue
|
4.2m
GBP
|
Operating Expenses
|
-35.2m
GBP
|
Operating Income
|
-31m
GBP
|
Other Expenses
|
-2.2m
GBP
|
Net Income
|
-33.2m
GBP
|
Free Cash Flow Analysis
Redx Pharma PLC
REDX Profitability Score
Profitability Due Diligence
Redx Pharma PLC's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
Score
Redx Pharma PLC's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
REDX Solvency Score
Solvency Due Diligence
Redx Pharma PLC's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Redx Pharma PLC's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
REDX Price Targets Summary
Redx Pharma PLC
Shareholder Return
REDX Price
Redx Pharma PLC
Average Annual Return | 180.13% |
Standard Deviation of Annual Returns | 335.38% |
Max Drawdown | -97% |
Market Capitalization | 31.4m GBX |
Shares Outstanding | 388 985 984 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Redx Pharma Plc engages in the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. The company is headquartered in Macclesfield, Cheshire and currently employs 71 full-time employees. The company went IPO on 2015-03-27. The Company’s product pipeline includes RXC004 and ROC007. Its lead product candidate RXC004, which is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. RXC004 is in Phase I study in combination with nivolumab (OPDIVO- Bristol Myers Squibb, an anti-PD-1 antibody). The RXC007 is a selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signaling pathway. RXC007 is used for the treatment of fibrotic diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one REDX stock under the Base Case scenario is 8.98 GBX.
Compared to the current market price of 8.06 GBX, Redx Pharma PLC is Undervalued by 10%.